3D Bioprinting: The Future of Organ Transplants and Longevity

Image: Unsplash

Imagine living in a world where the anxiety of waiting for an organ donor no longer exists. Think of a world where no one's future hangs by a thread because of a failing organ. 3D organ printing or bioprinting is emerging as a game changer and is set to shake the foundations of healthcare as we know it.

To quickly explain the concept of 3D bioprinting instead of ink these special printers use living cells to create layers that form tissues and organs. Incredibly, scientists are on the brink of making our own organs, tailor-made to fit our bodies.

Bioprinting traditionally mirrors 3D printing, which is currently transforming a range of industries such as manufacturing. However, instead of using materials like plastic or metal, bioprinters use bio-inks made up of living cells. These cells are then printed layer by layer, forming tissue structures and eventually entire organs.

The implications are profound, particularly for the field of transplantation where demand grossly outstrips supply. According to the Health Resources and Services Administration (HRSA) over one hundred thousand people are on the transplant waiting list in the United States, and sadly on average, seventeen people die each day waiting for organ transplants. As these statistics are only from the US (which is around 4% of the global population), one would expect those waiting for organ transplants currently to stretch into the millions worldwide.

As the technology evolves, we anticipate a future where transplant waiting lists shrink, and the risk of organ rejection diminishes due to doctors using cells harvested from the transplant recipients themselves.

By 2025, many experts expect that bioprinting will have cemented its place in pharmaceutical research and drug testing, given its capacity to produce accurate human tissue models already.

For example, The Wake Forest Institute for Regenerative Medicine (WFIRM) has recently successfully printed multilayered skin that was accepted by surrounding tissues and helped heal wounds more quickly.

As scientists continue to improve this technology and an influx in the number of laboratories and research institutions using bioprinters occurs, the ability to print fully functioning organs such as hearts or livers is around the corner.

By 2030, advances in bioprinting technologies and bio-ink development are expected to escalate, with the first set of clinical trials for printed organ transplants likely emerging. These trials will likely focus on less complex tissues like skin, sections of the liver, and simple blood vessels, which will set the foundation for more complicated organ printing in the future.

The real turning point is likely to occur around 2040. It is during this period that bioprinting could begin significantly supplementing organ donation, particularly for simpler organs.

By 2050, provided the technology continues to advance, and regulatory landscapes adapt, bioprinting could emerge as a standard response to organ failure, dramatically reducing dependency on organ donations.

What is clear is that advancements in 3D bioprinting technologies offer hope for so many people in the future and prolong their lives. By significantly reducing organ donor shortages, this promises a future of extended, healthier lives.

What is needed is a collective effort from scientists, ethicists, and legislators worldwide and a commitment to redefining the boundaries of life, health, and medical science.

As the very essence of human resilience and innovation comes to the fore, rewriting the narratives of survival, recovery, and longevity through bioprinting, in conjunction with advances in disease management, the future is looking brighter for Generation X, millennials, and beyond who may not have to face the anguish of sitting on organ transplant waiting lists like so many people today.

While this revolutionary technology could come a little late for baby boomers (who typically make up two-thirds of organ donor waitlists), although disease and illness often do not discriminate, but the stark reality is that so many organ failures are the direct result of aging. Therefore, in order to accelerate this technology so more lives can be saved in the coming decades, the more funding and effort that is put towards advancing bioprinting endeavours, the more immediate effect it will have in dramatically benefitting humanity and reducing loss and suffering in the world and improving patient outcomes.

According to the HRSA “every donor can save eight lives and enhance over 75 more.” Therefore, the need to accelerate bioprinting technologies may also become a necessity if, as expected, other age reversal therapies coming to market over the next few decades result in a longer-lived population, death rates decline, and the supply of desperately needed organs decreases.

The good news is that rapid transformations occurring in healthcare each day should give people of all generations greater hope than ever before that they can attain a longer lifespan and renewed health as each year ticks by.